Send us Feedback

Lorus Therapeutics Inc (LOR)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW
QUOTE AND NEWS
Lorus Therapeutics and Genentech Sign Global Intellectual Property License Agreement for IL-17E in Cancer
Marketwire  May 1  Comment 
TORONTO, ONTARIO -- (Marketwire) -- 05/01/12 -- Lorus Therapeutics Inc. (TSX:LOR) ("Lorus"), a biopharmaceutical company specializing in the discovery, research and development of pharmaceutical products and technologies for the management of cancer,
Lorus Therapeutics Reports Third Quarter Results for Fiscal Year 2012
Marketwire  Apr 12  Comment 
TORONTO, ONTARIO -- (Marketwire) -- 04/12/12 -- Lorus Therapeutics Inc. (TSX:LOR) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management
Lorus Therapeutics Announces Allowance of United States Patent for Anticancer Drug LOR-253
Marketwire  Apr 11  Comment 
TORONTO, ONTARIO -- (Marketwire) -- 04/11/12 -- Lorus Therapeutics Inc. (TSX:LOR) ("Lorus"), a biopharmaceutical company specializing in the discovery, research and development of pharmaceutical products and technologies for the management of cancer,
Lorus Therapeutics Presents Positive Data for Lead Anticancer Drug LOR-253
Marketwire  Apr 3  Comment 
TORONTO, ONTARIO -- (Marketwire) -- 04/03/12 -- Lorus Therapeutics Inc. (TSX:LOR) ("Lorus"), a biopharmaceutical company specializing in the discovery, research and development of pharmaceutical products and technologies for the management of cancer,
Lorus Therapeutics Announces Positive Results from Its Small Molecule Antimicrobial Program
Marketwire  Mar 27  Comment 
TORONTO, ONTARIO -- (Marketwire) -- 03/27/12 -- Lorus Therapeutics Inc. (TSX:LOR) ("Lorus"), a biopharmaceutical company specializing in the discovery, research and development of pharmaceutical products and technologies for the management of cancer,
Lorus Therapeutics Announces Issuance of Patent for Anticancer Drug LOR-253 in Canada
Marketwire  Mar 20  Comment 
TORONTO, ONTARIO -- (Marketwire) -- 03/20/12 -- Lorus Therapeutics Inc. (TSX:LOR) ("Lorus"), a biopharmaceutical company specializing in the discovery, research and development of pharmaceutical products and technologies for the management of cancer,
Lorus Therapeutics Presents Positive Data From Nonclinical Toxicity Studies on Lead Cancer Drug at Major Conference
Marketwire  Nov 8  Comment 
TORONTO, ONTARIO -- (Marketwire) -- 11/08/11 -- Lorus Therapeutics Inc. (TSX:LOR) ("Lorus"), today announced the presentation of positive nonclinical toxicity data for its lead small molecule anti-cancer drug candidate LOR-253 at the Annual Meeting
Lorus Therapeutics granted patent for clinical stage cancer drug
Canadian Business  May 3  Comment 
TORONTO - Biopharmaceutical company Lorus Therapeutics Inc. (TSX:LOR), says the U.S. Patent and Trademark Office has granted a patent for the
Biopharmaceutical company Lorus Therapeutics reports has Q3 net loss of $1.6M
Canadian Business  Apr 12  Comment 
TORONTO - Lorus Therapeutics Inc. (TSX:LOR) cited higher expenses, including research and development costs, for a wider loss in its fiscal 2011
Lorus Therapeutics Announces Publication on LOR-2040 Anticancer Activity in Acute Myeloid Leukemia
Marketwire  Feb 22  Comment 
TORONTO, ONTARIO -- (Marketwire) -- 02/22/11 -- Lorus Therapeutics Inc. (TSX: LOR) ("Lorus"), a biopharmaceutical company specializing in the discovery, research and development of pharmaceutical products and technologies for the management of




more ▼WIKI ANALYSIS
 The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.


 




References

Retrieved from "http://www.wikinvest.com/stock/Lorus_Therapeutics_Inc_(LOR)"
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki